G1 presents additional data from randomized Phase 2 trial in first-line SCLC
G1 Therapeutics announced data from new analyses of its randomized Phase 2 clinical trial of trilaciclib in combination with etoposide/carboplatin for the treatment of first-line small cell lung cancer. The analyses demonstrated clinically meaningful improvements for neutrophil, red blood cell and lymphocyte measures in patients treated with trilaciclib compared to placebo. With regard to lymphocytes, trilaciclib preserved or improved B cell and T cell subset counts, including activated CD8+ cells, and increased CD8+/regulatory T cell and activated CD8+/regulatory T cell ratios in peripheral blood compared to placebo. The company reported topline data from this trial in March 2018 showing robust myelopreservation benefits of trilaciclib. Consistent with previously reported results, new analyses demonstrated that trilaciclib reduced clinically relevant consequences of chemotherapy-induced myelosuppression versus placebo. Overall, there were fewer greater than or equal to Grade 3 treatment emergent adverse events with trilaciclib compared to placebo, mostly due to lower number of greater than or equal to Grade 3 hematologic TEAEs.